Axel Hauschild
University Hospital Schleswig-Holstein · 840 works · 74,665 citations · h-index 113
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial